World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
53157
World Ranking
8753
National Ranking
4513

Overview

Sai-Hong Ignatius Ou is affiliated with the University of California, Irvine, in the United States. Their research primarily focuses on medicine, with significant contributions in biochemistry, genetics, and molecular biology. Their work largely addresses pulmonary and respiratory medicine, oncology, molecular biology, cancer research, and pathology and forensic medicine.

They have published extensively on topics related to lung cancer treatments and mutations, lung cancer research studies, colorectal cancer treatments and studies, cancer genomics and diagnostics, lung cancer diagnosis and treatment, HER2/EGFR in cancer research, and cancer therapeutics and mechanisms.

Frequent co-authors collaborating with Sai-Hong Ignatius Ou include:

  • Misako Nagasaka
  • Viola W. Zhu
  • Shirish M. Gadgeel
  • D. Ross Camidge
  • Shannon Zhang

They have contributed to numerous publications in high-impact journals, including:

  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Lung Cancer Targets and Therapy
  • JTO Clinical and Research Reports
  • Lung Cancer

Significant recent papers authored or co-authored by Sai-Hong Ignatius Ou cover topics such as targeted therapies for cancers with specific genetic mutations, reflecting advances in precision oncology:

  • First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1), 2022, Journal of Clinical Oncology
  • Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation, 2022, New England Journal of Medicine
  • Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C, 2022, New England Journal of Medicine
  • Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration, 2020, Nature Medicine
  • Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC, 2024, New England Journal of Medicine

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

    James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai

  • The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients

    Jill Hallin;Lars D. Engstrom;Lauren Hargis;Andrew Calinisan

  • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study

    Shirish M. Gadgeel;Leena Gandhi;Gregory J. Riely;Alberto A. Chiappori

  • Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

    Garrett M. Frampton;Siraj M. Ali;Mark Rosenzweig;Juliann Chmielecki

  • Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

    Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel

  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Benjamin J. Solomon;Benjamin Besse;Benjamin Besse;Todd M. Bauer;Enriqueta Felip

  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

    Alice T Shaw;Leena Gandhi;Shirish Gadgeel;Gregory J Riely

  • Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study

    Sai Hong Ignatius Ou;Jin Seok Ahn;Luigi De Petris;Ramaswamy Govindan

  • Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

    Daniel B. Costa;Alice T. Shaw;Sai-Hong I. Ou;Benjamin J. Solomon

  • ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

    Justin F. Gainor;Anna M. Varghese;Sai-Hong Ignatius Ou;Sheheryar Kabraji

  • Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

    Sai Hong Ignatius Ou;Eunice L. Kwak;Christina Siwak-Tapp;Joni Dy

  • Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial

    James Chih Hsin Yang;Jin Yuan Shih;Wu Chou Su;Te Chun Hsia

  • Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Alexander Drilon;Sai Hong Ignatius Ou;Byoung Chul Cho;Dong Wan Kim

Frequent Co-Authors

Alice T. Shaw
Alice T. Shaw Harvard University
Siraj M. Ali
Siraj M. Ali Foundation Medicine
D. Ross Camidge
D. Ross Camidge University of Colorado Anschutz Medical Campus
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Shirish M. Gadgeel
Shirish M. Gadgeel University of Michigan–Ann Arbor
Jeffrey S. Ross
Jeffrey S. Ross Foundation Medicine
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Philip J. Stephens
Philip J. Stephens Foundation Medicine
Jeffrey W. Clark
Jeffrey W. Clark Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA often requires many years of education and training, there are a range of related online degrees that can open doors to healthcare careers. For those interested in leadership and administration roles, consider exploring the cheapest mha programs online healthcare. These programs can help you advance into management positions within medical institutions and clinics.

If you are aiming for advanced nursing practice, pursuing the cheapest dnp program gives you the clinical expertise needed for top nursing roles. Likewise, for those interested in pharmaceuticals, enrolling in a pharmacy degree online can lead to careers in pharmacy or pharmaceutical sciences.

For individuals drawn to the intersection of health and technology, a bachelor of health information management online offers the skills needed to manage healthcare data and support patient outcomes. These online degrees provide flexible, affordable options for advancing your career and contributing to the health sector beyond traditional medical practice.

Best Scientists Citing Sai-Hong Ignatius Ou

Trending Scientists

Recently Published Articles